Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 7/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | PRKACG | P22612 | 2/20 | 0.45 |
| ▸ | PRKACB | P22694 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173980 | 0.86 | CNR2 (0.51) | CNR2CNR1HTR6NPSR1PRKACA | |
| SCHEMBL13490778 | 0.76 | CNR2 (0.56) | CNR2CNR1NPSR1PRKACAPRKACG | |
| SCHEMBL4604002 | 0.75 | CNR2 (0.55) | CNR2CNR1NPSR1PRKACAPRKACG | |
| SCHEMBL2173879 | 0.75 | CA2 (0.54) | — | |
| SCHEMBL4603995 | 0.74 | NPSR1 (0.57) | CNR2CNR1NPSR1PRKACAPRKACG | |
| SCHEMBL24199359 | 0.74 | CNR2 (0.53) | CNR2CNR1NPSR1PRKACAPRKACG | |
| SCHEMBL1518274 | 0.74 | POLB (0.71) | CNR2CNR1NPSR1 | |
| SCHEMBL6042188 | 0.72 | CNR2 (0.70) | CNR2CNR1NPSR1 | |
| SCHEMBL8758217 | 0.72 | HTR2A (0.60) | CNR2CNR1HTR6NPSR1 | |
| SCHEMBL24199374 | 0.72 | CNR2 (0.52) | CNR2CNR1NPSR1PRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | CNR2 4519/4885CNR1 3758/4885HTR6 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.